{"id":47800,"date":"2023-12-12T13:48:27","date_gmt":"2023-12-12T05:48:27","guid":{"rendered":"https:\/\/biopioneer.com.tw\/?p=47800"},"modified":"2023-12-12T17:58:13","modified_gmt":"2023-12-12T09:58:13","slug":"her2-erbb2-protein-human-recombinant-ecd-his-tag-hplc-verified%e8%b2%a8%e8%99%9f10004-h08h","status":"publish","type":"post","link":"https:\/\/biopioneer.com.tw\/?p=47800","title":{"rendered":"Her2\/ERBB2 Protein, Human, Recombinant (ECD, His Tag), HPLC-verified\u8ca8\u865f10004-H08H"},"content":{"rendered":"

Her2\/ERBB2 \u91cd\u7d44\u86cb\u767d\uff08ECD\uff0cHis \u6a19\u7c64\uff09 | SinoBiological\u8ca8\u865f10004-H08H<\/a><\/span><\/h4>\n

Purity: > 90 % as determined by SDS-PAGE. > 90 % as determined by SEC-HPLC.<\/p>\n

\"Logo\"<\/p>\n

\u7522\u54c1\u4ecb\u7d39<\/strong>:<\/strong><\/span>\u4eba\u8868\u76ae\u751f\u9577\u56e0\u5b50\u53d7\u9ad4 2 (Human epidermal growth factor receptor 2, HER2)\uff0c\u4e5f\u7a31\u70ba ErbB2\u3001NEU \u548c CD340\uff0c\u662f\u4e00\u7a2e I \u578b\u819c\u7cd6\u86cb\u767d(type I membrane glycoprotein )\uff0c\u5c6c\u65bc\u8868\u76ae\u751f\u9577\u56e0\u5b50 (epidermal growth factor, EGF) \u53d7\u9ad4\u5bb6\u65cf\u3002 HER2\u86cb\u767d\u7531\u65bc\u7f3a\u4e4f\u81ea\u8eab\u7684\u914d\u9ad4\u7d50\u5408\u57df(ligand binding domain)\u800c\u4e0d\u80fd\u7d50\u5408\u751f\u9577\u56e0\u5b50\uff0c\u4e26\u4e14\u662f\u7d44\u6210\u6027\u7684\u81ea\u6291\u5236( autoinhibited constitutively)\u3002\u7136\u800c\uff0cHER2 \u8207\u5176\u4ed6\u914d\u9ad4\u7d50\u5408\u7684 EGF \u53d7\u9ad4\u5bb6\u65cf\u6210\u54e1\u5f62\u6210\u7570\u4e8c\u805a\u9ad4\uff0c\u56e0\u6b64\u7a69\u5b9a\u914d\u9ad4\u7d50\u5408( ligand binding)\u4f75\u589e\u5f37\u6fc0\u9176\u4ecb\u5c0e( kinase-mediated activation)\u7684\u4e0b\u6e38\u5206\u5b50\u6fc0\u6d3b\u3002 HER2 \u5728\u767c\u80b2(development)\u3001\u7d30\u80de\u589e\u6b96(cell proliferation)\u548c\u5206\u5316(differentiation)\u4e2d\u767c\u63ee\u8457\u95dc\u9375\u4f5c\u7528\u3002\u64da\u5831\u5c0e\uff0cHER2\u57fa\u56e0\u8207\u591a\u7a2e\u764c\u75c7\u7684\u60e1\u6027\u816b\u7624(malignancy)\u548c\u4e0d\u826f\u9810\u5f8c\u76f8\u95dc\uff0c\u5305\u62ec\u4e73\u817a\u764c(breast)\u3001\u524d\u5217\u817a\u764c(prostate)\u3001\u5375\u5de2\u764c(ovarian)\u3001\u80ba\u764c( lung cancers )\u7b49\u3002<\/p>\n

SinoBiological\u63d0\u4f9b\u91cd\u7d44\u86cb\u767d\u7cfb\u5217\u5546\u54c1\uff1b\u5176\u4e2dHer2\/ERBB2 \u91cd\u7d44\u86cb\u767d\uff08ECD\uff0cHis \u6a19\u7c64\uff09\uff0c\u86cb\u767d\u8cea\u5efa\u69cb(rotein Construction)\u70ba\u4eba\u985eErbB2 (NP_004439.2)\u80de\u5916\u7d50\u69cb\u57df(Met 1-Thr 652)\u7684DNA\u5e8f\u5217\u8207C\u7aef\u7684\u591a\u7d44\u80fa\u9178\u6a19\u7c64\u878d\u5408\uff0cAccession#NP_004439.2\u3002\u8868\u9054\u7684\u5bbf\u4e3bHEK293\u7d30\u80de\u3002\u4ee5 SDS-PAGE \u6e2c\u5b9a\u7d14\u5ea6> 90 %\u3002\u4ee5 SEC-HPLC \u6e2c\u5b9a\uff0c> 90%\u3002\u4ee5 LAL \u65b9\u6cd5\u6e2c\u5b9a\uff0c\u5167\u6bd2\u7d20< 1.0 EU\/\u03bcg \u86cb\u767d\u8cea\u3002\u5206\u5b50\u91cf\u91cd\u7d44\u4ebaErbB2\u542b\u6709641\u500b\u80fa\u57fa\u9178\uff0c\u8a08\u7b97\u5206\u5b50\u91cf\u70ba71 kDa\u3002\u7531\u65bc\u7cd6\u57fa\u5316\uff0crh ErbB2 \u5728\u9084\u539f\u689d\u4ef6\u4e0b\u5728 SDS-PAGE \u4e2d\u9077\u79fb\u70ba\u5927\u7d04 100-110 kDa \u7684\u86cb\u767d\u8cea\u3002<\/p>\n

<\/p>\n

Measured by its ability to block anti-ErbB2 mediated inhibition of BT474 human breast ductal carcinoma cell proliferation. The ED50<\/sub>\u00a0for this effect is 0.2-1 \u03bcg\/mL in the presence of 0.6 \u00b5g\/mL Anti-ErbB2\/Her2 Monoclonal Antibody.<\/div>\n
<\/div>\n
<\/div>\n
Immobilized Her2\/ERBB2 Protein, Human, Recombinant (ECD, His Tag)(Cat:10004-H08H) at 2 \u03bcg\/ml (100 \u03bcl\/well) can bind Anti-Erbb2 Antibody (Trastuzumab)(Cat:68046-H002), the EC50<\/sub>\u00a0is 10-60 ng\/mL.<\/div>\n
<\/div>\n
<\/div>\n
Captured anti-Her2 IgG1 antibody on proA Chip can bind Her2 (Cat.No.10004-H08H) with\u00a0an\u00a0affinity constant of 3.270 nM\u00a0as determined\u00a0in a SPR assay (Biacore\u00a0T200) (Routinely tested).<\/div>\n
<\/div>\n
<\/div>\n
Captured Trastuzumab (68046-H002) on\u00a0proA Chip can bind Her2 (Cat.No.10004-H08H) with an affinity constant of 3.727 nM as determined\u00a0in a SPR\u00a0assay (Biacore\u00a0T200) (Routinely\u00a0tested).<\/div>\n
<\/div>\n
<\/div>\n
Loaded Anti-Erbb2 Antibody (Trastuzumab) on ProA Biosensor, can bind Recombinant Human Her2\/ERBB2 Protein, His Tag (Cat. No. 10004-H08H) with an affinity constant of 0.547 nM as determined in BLI assay (Sartorius Octet RED384) (Routinely tested).<\/div>\n
<\/div>\n
Activity<\/div>\n
1. Immobilized Her2\/ERBB2 Protein, Human, Recombinant (ECD, His Tag)(Cat:10004-H08H) at 2 \u03bcg\/ml (100 \u03bcl\/well) can bind Anti-Erbb2 Antibody (Trastuzumab)(Cat:68046-H002), the EC50<\/sub>\u00a0is 10-60 ng\/mL.
\n2. Measured by its ability to block anti-ErbB2 mediated inhibition of BT474 human breast ductal carcinoma cell proliferation. The ED50<\/sub>\u00a0for this effect is 0.2-1 \u03bcg\/mL in the presence of 0.6 \u00b5g\/mL Anti-ErbB2\/Her2 Monoclonal Antibody.
\n3.Captured anti-Her2 IgG1 antibody on proA Chip can bind Her2 (Cat.No.10004-H08H) with\u00a0an\u00a0affinity constant of 3.270 nM\u00a0as determined\u00a0in a SPR assay (Biacore\u00a0T200) (Routinely tested).
\n4.Captured Trastuzumab (68046-H002) on\u00a0proA Chip can bind Her2 (Cat.No.10004-H08H) with an affinity constant of 3.727 nM as determined\u00a0in a SPR\u00a0assay (Biacore\u00a0T200)(Routinely tested).
\n5.Loaded Anti-Erbb2 Antibody (Pertuzumab) on ProA Biosensor, can bind Recombinant Human Her2\/ERBB2 Protein, His Tag (Cat. No. 10004-H08H) with an affinity constant of 0.382 nM as determined in BLI assay (Sartorius Octet RED384) (Routinely tested).
\n6.Loaded Anti-Erbb2 Antibody (Trastuzumab) on ProA Biosensor, can bind Recombinant Human Her2\/ERBB2 Protein, His Tag (Cat. No. 10004-H08H) with an affinity constant of 0.547 nM as determined in BLI assay (Sartorius Octet RED384) (Routinely tested).<\/div>\n
<\/div>\n
<\/div>\n
\n

Krawczyk N,\u00a0et al.<\/em> (2009) HER2 status on persistent disseminated tumor cells after adjuvant therapy may differ from initial HER2 status on primary tumor. Anticancer Res. 29(10): 4019-24.<\/p>\n<\/div>\n

\n
\n
\"\u7db2\u7ad9\u898f\u683c\u5c0f\u5716<\/div>\n<\/div>\n
\n
Sino Biological Inc. \u70ba\u5168\u7403\u751f\u91ab\u88fd\u85e5\u7814\u7a76\u9818\u57df\u4e2d\u6700\u5927\u7684cDNA\u3001\u91cd\u7d44\u86cb\u767d\u8cea\u548c\u6297\u9ad4\u88fd\u9020\u4f9b\u61c9\u5546\u4e4b\u4e00\uff0c\u8fd1\u5e74\u4f86\u66f4\u81f4\u529b\u65bc\u751f\u7522\u7814\u767c\u81e8\u5e8a\u7528GMP\u7b49\u7d1a\u91cd\u7d44\u86cb\u767d\u8cea(GMP Recombinant Protein)\u3002Sino Biological\u5728\u6d41\u611f\u75c5\u6bd2\u7b49\u88fd\u75c5\u6027\u75c5\u6bd2\u7814\u767c\u5feb\u901f\u9818\u5148\u5168\u7403\u3002Sino Biological Inc\u5718\u968a\u64c1\u6709\u591a\u5e74\u91cd\u7d44\u86cb\u767d\u7814\u767c\u7d93\u9a57\u3002\u591a\u5e74\u4f86\uff0c\u6211\u5011\u7684\u5718\u968a\u5df2\u7d93\u751f\u6210\u4e86\u8d85\u904e6000\u7a2e\u91cd\u7d44\u86cb\u767d(recombinant proteins)\uff0c\u6db5\u84cb\u4e86\u514d\u75ab\u6aa2\u67e5\u9ede(immune checkpoints)\u3001\u6297\u9ad4\u85e5\u7269\u9776\u9ede(antibody drug targets)\u3001CAR-T\u7d30\u80de\u6cbb\u7642\u9776\u9ede(\u00a0CAR-T cell therapy targets)\u3001Fc\u53d7\u9ad4(Fc receptors)\u3001\u6d41\u611f\u75c5\u6bd2\u86cb\u767d(\u00a0influenza viral proteins)\u548c\u7d30\u80de\u56e0\u5b50(cytokines)\u7b49\u6700\u71b1\u9580\u7684\u7814\u7a76\u9818\u57df\u3002\u91cd\u7d44\u86cb\u767d\u5177\u6709\u9ad8\u7d14\u5ea6\u548c\u7d93\u904e\u9a57\u8b49\u7684\u751f\u7269\u6d3b\u6027\uff0c\u53ef\u4ee5\u652f\u6301\u60a8\u5f9e\u751f\u7269\u88fd\u85e5\u9776\u9ede\u767c\u73fe\u3001\u86cb\u767d\u8cea\u7d50\u69cb\u548c\u529f\u80fd\u5206\u6790\u3001\u7d30\u80de\u6cbb\u7642\u548c\u91cd\u7d44\u9176\u8868\u5fb5\u7b49\u65b9\u9762\u7684\u79d1\u5b78\u7814\u7a76\u3002<\/div>\n
<\/div>\n
\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Catalog #<\/strong><\/td>\nSpecies<\/strong><\/td>\nMolecule<\/strong><\/td>\nApplication<\/strong><\/td>\n<\/tr>\n
10084-R015<\/a><\/td>\nHuman<\/td>\nCD274<\/td>\nELISA, IHC-P<\/td>\n<\/tr>\n
10004-R511<\/a><\/td>\nHuman<\/td>\nERBB2<\/td>\nELISA, ELISA(Cap), FCM, lCC\/IF, IF<\/td>\n<\/tr>\n
10565-R102<\/a><\/td>\nHuman<\/td>\nCD226<\/td>\nELISA<\/td>\n<\/tr>\n
10231-R301-P<\/a><\/td>\nHuman<\/td>\nLDLR<\/td>\nFCM<\/td>\n<\/tr>\n
10259-R110<\/a><\/td>\nHuman<\/td>\nFCGR2B<\/td>\nWB, IHC-P, IP<\/td>\n<\/tr>\n
10773-R023<\/a><\/td>\nHuman<\/td>\nASGR1<\/td>\nELISA<\/td>\n<\/tr>\n
10004-R002<\/a><\/td>\nHuman<\/td>\nERBB2<\/td>\nELISA, IHC-P, FCM, ICC\/IF, IF<\/td>\n<\/tr>\n
10001-R021<\/a><\/td>\nHuman<\/td>\nEGFR<\/td>\nWB, ELISA, ELISA(Det), ICC\/IF, IF, IP<\/td>\n<\/tr>\n
10694-R028<\/a><\/td>\nHuman<\/td>\nEpCAM<\/td>\nWB, ELISA, ELISA(Det), IHC-P, FCM, ICC\/IF, IF, IP<\/td>\n<\/tr>\n
13909-R226<\/a><\/td>\nHuman<\/td>\nF8<\/td>\nELISA<\/td>\n<\/tr>\n
10005-R017<\/a><\/td>\nHuman<\/td>\nPVRL2<\/td>\nELISA<\/td>\n<\/tr>\n
10377-RD67<\/a><\/td>\nHuman<\/td>\nPDCD1<\/td>\nELISA, IHC-P<\/td>\n<\/tr>\n
10594-RM03<\/a><\/td>\nHuman<\/td>\nPCSK9<\/td>\nELISA<\/td>\n<\/tr>\n
10186-R125<\/a><\/td>\nHuman<\/td>\nBSG<\/td>\nWB, ELISA, IHC-P, FCM, ICC\/IF, IF, IP<\/td>\n<\/tr>\n
10136-R111-P<\/td>\nHuman<\/td>\nFLT1<\/td>\nFCM<\/td>\n<\/tr>\n
10390-R024<\/a><\/td>\nHuman<\/td>\nHAVCR2<\/td>\nELISA, ELISA(Cap)<\/td>\n<\/tr>\n
10390-R108<\/a><\/td>\nHuman<\/td>\nHAVCR2<\/td>\nELISA<\/td>\n<\/tr>\n
11066-R105<\/a><\/td>\nHuman<\/td>\nVEGFA<\/td>\nELISA<\/td>\n<\/tr>\n
11215-R107<\/a><\/td>\nHuman<\/td>\nLAMP1<\/td>\nWB, ELISA, IHC-P, FCM, ICC\/IF, IF, IP<\/td>\n<\/tr>\n
11235-R019<\/a><\/td>\nHuman<\/td>\nREG3A<\/td>\nELISA, IHC-P<\/td>\n<\/tr>\n
10973-R111<\/a><\/td>\nHuman<\/td>\nvWF<\/td>\nELISA, ELISA(Det), IHC-P<\/td>\n<\/tr>\n
11050-R412<\/a><\/td>\nHuman<\/td>\nNGF<\/td>\nELISA<\/td>\n<\/tr>\n
11279-R021<\/a><\/td>\nHuman<\/td>\nCTNNB1<\/td>\nELISA, IHC-P, ICC\/IF, IF, IP<\/td>\n<\/tr>\n
13908-R002<\/a><\/td>\nHuman<\/td>\nASGR2<\/td>\nELISA, IHC-P, FCM, ICC\/IF, IF<\/td>\n<\/tr>\n
10008-R064<\/a><\/td>\nHuman<\/td>\nVEGFA<\/td>\nELlSA, ELISA(Det)<\/td>\n<\/tr>\n
100087-R013<\/a><\/td>\nHuman<\/td>\nFGF2<\/td>\nHC-P<\/td>\n<\/tr>\n
10014-R101<\/a><\/td>\nHuman<\/td>\nFGF2<\/td>\nELISA<\/td>\n<\/tr>\n
100393-R024-F<\/a><\/td>\nHuman<\/td>\nGPC3<\/td>\nFCM<\/td>\n<\/tr>\n
100393-R024-P<\/a><\/td>\nHuman<\/td>\nGPC3<\/td>\nFCM<\/td>\n<\/tr>\n
10084-R001<\/a><\/td>\nHuman<\/td>\nCD274<\/td>\nELISA<\/td>\n<\/tr>\n
10231-R301-F<\/a><\/td>\nHuman<\/td>\nLDLR<\/td>\nFCM<\/td>\n<\/tr>\n
10289-R102<\/a><\/td>\nHuman<\/td>\nLGALS3<\/td>\nHC-P<\/td>\n<\/tr>\n
10400-R113<\/a><\/td>\nHuman<\/td>\nCD4<\/td>\nEIISA, IHC-P<\/td>\n<\/tr>\n
10417-R006<\/a><\/td>\nHuman<\/td>\nTNFRSF1B<\/td>\nELISA<\/td>\n<\/tr>\n
10980-R081<\/a><\/td>\nHuman<\/td>\nCD8A<\/td>\nHC-P<\/td>\n<\/tr>\n
11051-Rn208<\/a><\/td>\nHuman<\/td>\nHAVCR1<\/td>\nELISA<\/td>\n<\/tr>\n
12078-R001<\/a><\/td>\nHuman<\/td>\nGLA<\/td>\nW8, ELISA, IP<\/td>\n<\/tr>\n
10007-R104<\/a><\/td>\nHuman<\/td>\nCSF3<\/td>\nELISA<\/td>\n<\/tr>\n
10073-R001<\/a><\/td>\nHuman<\/td>\nCD14<\/td>\nIHC-P<\/td>\n<\/tr>\n
10160-R005<\/a><\/td>\nHuman<\/td>\nCFD<\/td>\nELISA<\/td>\n<\/tr>\n
10259-R112<\/a><\/td>\nHuman<\/td>\nFCGR2B<\/td>\nELISA.ELISA(Det)<\/td>\n<\/tr>\n
10327-RM04<\/a><\/td>\nHuman<\/td>\nMMP9<\/td>\nELISA<\/td>\n<\/tr>\n
10995-R018<\/a><\/td>\nHuman<\/td>\nSerpinG1<\/td>\nWB, ELISA, ELISA(Det), IP<\/td>\n<\/tr>\n
11031-R039<\/a><\/td>\nHuman<\/td>\nCD8B<\/td>\nHC-P<\/td>\n<\/tr>\n
11192-R179<\/a><\/td>\nHuman<\/td>\nCD68<\/td>\nHC-P<\/td>\n<\/tr>\n
11996-R351<\/a><\/td>\nHuman<\/td>\nKIT<\/td>\nELISA, IHC-P<\/td>\n<\/tr>\n
12163-R005<\/a><\/td>\nHuman<\/td>\nVSIG4<\/td>\nELISA, ELISA(Det)<\/td>\n<\/tr>\n
13908-R002-P<\/a><\/td>\nHuman<\/td>\nASGR2<\/td>\nFCM<\/td>\n<\/tr>\n
100128-R001<\/a><\/td>\nHuman<\/td>\nCD79A<\/td>\nIHC-P<\/td>\n<\/tr>\n
100129-R101<\/a><\/td>\nHuman<\/td>\nKRT14<\/td>\nWB, IHC-P, IP<\/td>\n<\/tr>\n
100254-R211<\/a><\/td>\nHuman<\/td>\nVIM<\/td>\nIHC-P<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Her2\/ERBB2 \u91cd\u7d44\u86cb\u767d\uff08ECD\uff0cHis \u6a19\u7c64\uff09 | SinoBiological\u8ca8\u865f10004-H08 […]<\/p>\n","protected":false},"author":3,"featured_media":47802,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[5550],"tags":[6443,6445,6446,1268,6444],"_links":{"self":[{"href":"https:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/posts\/47800"}],"collection":[{"href":"https:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/biopioneer.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=47800"}],"version-history":[{"count":3,"href":"https:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/posts\/47800\/revisions"}],"predecessor-version":[{"id":47805,"href":"https:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/posts\/47800\/revisions\/47805"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/media\/47802"}],"wp:attachment":[{"href":"https:\/\/biopioneer.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=47800"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/biopioneer.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=47800"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/biopioneer.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=47800"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}